Quarterly report pursuant to Section 13 or 15(d)

Subsequent Event - Additional Information (Detail)

v3.7.0.1
Subsequent Event - Additional Information (Detail) - Pfizer [Member] - Subsequent Event [Member]
May 10, 2017
USD ($)
Subsequent Event [Line Items]  
Potential amount eligible to receive for milestones payments $ 475,000,000
Up-front Payment Arrangement [Member]  
Subsequent Event [Line Items]  
Payments receive under collaboration agreement 70,000,000
Maximum [Member] | SB-525 [Member]  
Subsequent Event [Line Items]  
Potential amount eligible to receive for milestones payments 300,000,000
Maximum [Member] | Other Products [Member]  
Subsequent Event [Line Items]  
Potential amount eligible to receive for milestones payments $ 175,000,000